October was a volatile month for the markets, and biotech stocks were no exception. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB) had slipped about 17 percent in the period. This compares to S&P 500 s 7 percent retreat.
As we enter the last leg of the year, here are a few PDUFA. Read More.
Baudax Bio Strengthens Management Team with Appointment of Richard S. Casten as Chief Financial Officer Company Also Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
March 08, 2021 07:00 ET | Source: Baudax Bio, Inc. Baudax Bio, Inc. Malvern, Pennsylvania, UNITED STATES
MALVERN Pa., March 08, 2021 (GLOBE NEWSWIRE) Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced the appointment of Richard S. Casten, CPA, MBA as Chief Financial Officer. In this role, Mr. Casten will be responsible for leading and directing the financial activities of the Company. Mr. Casten brings to Baudax 25 years of diversified financial experience across pharmaceutical, Fortune 500 consumer products and public accounting. He replaces Ryan D. Lake, CPA who is transitioning to full time Chief Financial Officer for Recro.
Baudax Bio to Present at the H C Wainwright Global Life Sciences Conference yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
Recro Announces Executive Changes David Enloe Named President and Chief Executive Officer
December 16, 2020 07:00 ET | Source: Recro Pharma, Inc. Recro Pharma, Inc. Malvern, Pennsylvania, UNITED STATES
MALVERN, Pa., Dec. 16, 2020 (GLOBE NEWSWIRE) Recro (Nasdaq:REPH), a leading contract development and manufacturing organization (CDMO), with integrated solutions for formulation, analytical services, regulatory support, manufacturing and packaging of both commercial and development stage oral solid dose drug products, today announced that David Enloe has been named President, Chief Executive Officer and a member of the Company’s Board of Directors, replacing Gerri Henwood, effective today.
Mr. Enloe brings over two decades of executive leadership experience in biotechnology, clinical drug development and GMP manufacturing to Recro, with a proven track record of building and growing CDMO businesses. Most recentl
Published: Dec 16, 2020
MALVERN, Pa., Dec. 16, 2020 (GLOBE NEWSWIRE) Recro (Nasdaq:REPH), a leading contract development and manufacturing organization (CDMO), with integrated solutions for formulation, analytical services, regulatory support, manufacturing and packaging of both commercial and development stage oral solid dose drug products, today announced that David Enloe has been named President, Chief Executive Officer and a member of the Company’s Board of Directors, replacing Gerri Henwood, effective today.
Mr. Enloe brings over two decades of executive leadership experience in biotechnology, clinical drug development and GMP manufacturing to Recro, with a proven track record of building and growing CDMO businesses. Most recently, he served as President and Chief Executive Officer of Ajinomoto Bio-Pharma Services, a global, fully integrated CDMO. Under Mr. Enloe’s leadership, Aji Bio-Pharma’s revenues have increased over 50% in a four-year period and he led the